Transplantation of neural stem cells co-transfected with Nurr1 and Brn4 for treatment of Parkinsonian rats.
Tan X, Zhang L, Qin J, Tian M, Zhu H, Dong C, Zhao H, Jin G
Transplanting neural stem cells engineered to overexpress Nurr1 and Brn4 restores dopamine levels and reverses motor deficits in rats with Parkinsonian symptoms. This preclinical study demonstrates that co-expressing these transcription factors significantly improves the maturity, viability, and therapeutic efficacy of transplanted dopaminergic neurons.
- Co-expression of Nurr1 and Brn4 boosts dopamine production in rat brains.
- Engineered stem cells reverse motor deficits in Parkinsonian animal models.
- The study uses rats, not humans, limiting direct clinical applicability.
- Results support cell replacement therapy strategies for dopaminergic loss.
An Engraftable Human Embryonic Stem Cell Neuronal Lineage-Specific Derivative Retains Embryonic Chromatin Plasticity for Scale-Up CNS Regeneration.
Parsons XH
This study demonstrates that human embryonic stem cells can be efficiently converted into pure, engraftable neuronal progenitors that integrate well into the brain. These cells retain high plasticity and exclusively generate neurons without forming glial cells, offering a scalable source for potential CNS regeneration therapies.
- Stem cells convert to pure neuronal progenitors with high efficiency using retinoic acid.
- Engrafted cells integrate well into the brain and yield human neurons.
- Cells do not form glial cells, ensuring lineage-specific differentiation.
- The method provides a scalable supply of neuronal progenitors for therapy.
Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease.
Zhang Z, Li X, Xie WJ, Tuo H, Hintermann S, Jankovic J, Le W
A synthetic compound that activates the Nurr1 protein protects dopamine-producing neurons and improves motor function in mice with experimentally induced Parkinson's disease. This preclinical study demonstrates that boosting Nurr1 activity can counteract neurodegeneration in an animal model, suggesting a potential therapeutic avenue for future research.
- The study uses mice, not humans, to test the effects of the drug.
- A synthetic activator increased Nurr1 levels and protected dopamine neurons.
- Treated mice showed improved motor coordination compared to untreated controls.
- The treatment reduced inflammation and preserved dopamine transporters in the brain.
Association of Nurr1 gene mutations with Parkinson's disease in the Han population living in the Hubei province of China.
Lou X, Liao W
This study identifies specific genetic variations in the NR4A2 gene that are more common in Chinese patients with Parkinson's disease and correlate with lower gene expression levels. These findings suggest that these particular mutations may contribute to the development of Parkinson's disease in this population.
- Researchers sequenced the NR4A2 gene in 200 Chinese Parkinson's patients and 200 healthy controls.
- Two specific genetic variations were found more frequently in patients than in healthy individuals.
- Patients with these variations showed significantly lower levels of NR4A2 gene expression.
- The study links these genetic changes to the pathogenesis of Parkinson's disease.
MANF regulates dopaminergic neuron development in larval zebrafish.
Chen YC, Sundvik M, Rozov S, Priyadarshini M, Panula P
MANF supports the development of dopamine-producing neurons in zebrafish, and its protein can partially compensate for the loss of NR4A2 function. This suggests a potential biological link between MANF activity and the dopaminergic deficits seen in NR4A2-related syndromes.
- MANF knockdown reduces dopamine levels and specific neuron counts in zebrafish larvae.
- Exogenous MANF mRNA rescues these developmental defects in normal larvae.
- MANF partially restores dopaminergic neurons lost in NR4A2-deficient larvae.
- This is a preclinical study using zebrafish models, not human trials.
Specification of midbrain dopamine neurons from primate pluripotent stem cells.
Xi J, Liu Y, Liu H, Chen H, Emborg ME, Zhang SC
Researchers developed a method to create functional midbrain dopamine neurons from human and monkey stem cells using specific chemical signals. This technique produces enriched populations of these neurons that exhibit key molecular and electrical characteristics, offering a platform for disease modeling and drug testing.
- The protocol generates midbrain dopamine neurons from human and primate stem cells.
- Chemical inhibitors and growth factors direct cell fate toward the midbrain floor plate.
- Resulting neurons express Nurr1, tyrosine hydroxylase, and other midbrain markers.
- Cells display typical electrophysiological properties of mature dopamine neurons.
- The system supports disease modeling, drug screening, and potential cell therapy research.
Genetic analysis of NR4A2 gene in a large population of Han Chinese patients with Parkinson's disease.
Liu H, Tao Q, Deng H, Ming M, Ding Y, Xu P, Chen S, Song Z, Le W
This study identifies several NR4A2 gene variants in Chinese patients with Parkinson's disease, suggesting the gene contributes to susceptibility for this condition. It confirms that NR4A2 plays a role in dopaminergic neuron health across different populations.
- Researchers sequenced the NR4A2 gene in nearly 700 Chinese Parkinson's patients and controls.
- Four novel variants were found exclusively in patients with Parkinson's disease.
- Six other variants appeared in both patients and healthy controls at varying frequencies.
- Results suggest NR4A2 is a susceptibility gene for Parkinson's in this population.
Dopaminergic neurons from midbrain-specified human embryonic stem cell-derived neural stem cells engrafted in a monkey model of Parkinson's disease.
Daadi MM, Grueter BA, Malenka RC, Redmond DE, Steinberg GK
Human neural stem cells differentiated into dopamine-producing neurons survive and integrate in a monkey model of Parkinson's disease. This preclinical study demonstrates that these engineered cells maintain their functional phenotype after transplantation.
- Midbrain-specified human neural stem cells differentiate into dopamine neurons using specific growth factors.
- Transplanted cells survive, extend neurites, and express synaptic markers in a primate Parkinson's model.
- This is animal research with no direct clinical data for NR4A2-related syndromes.
Conditional expression of Parkinson's disease-related mutant α-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1.
Lin X, Parisiadou L, Sgobio C, Liu G, Yu J, Sun L, Shim H, Gu XL, Luo J, Long CX, Ding J, Mateo Y, Sullivan PH, Wu LG, Goldstein DS, Lovinger D, Cai H
This study shows that mutant alpha-synuclein, a protein linked to Parkinson's disease, causes the loss of Nurr1 (NR4A2) protein in mouse brain cells. Preventing this Nurr1 degradation protects these neurons from damage in the mouse model.
- Mutant alpha-synuclein triggers the breakdown of Nurr1 protein in mouse dopaminergic neurons.
- Stopping Nurr1 degradation reduces neuron loss in this Parkinson's mouse model.
- The research uses transgenic mice, not human patients or clinical trials.
Identification of embryonic stem cell-derived midbrain dopaminergic neurons for engraftment.
Ganat YM, Calder EL, Kriks S, Nelander J, Tu EY, Jia F, Battista D, Harrison N, Parmar M, Tomishima MJ, Rutishauser U, Studer L
This study identifies a specific developmental stage of stem-cell-derived dopamine neurons that successfully engrafts and improves motor function in Parkinson's disease mice. The research demonstrates that cells marked by the Nurr1 protein at this middle differentiation stage offer the best survival and therapeutic potential for transplantation.
- Researchers used mouse embryonic stem cells to create midbrain dopamine neurons for therapy.
- Cells purified at the Nurr1-positive middle stage showed the highest survival after transplant.
- These specific grafts significantly improved motor deficits in Parkinson's disease mice.
- The study confirms that precise cell purification reduces risks and enhances therapeutic outcomes.
Cooperation of nuclear fibroblast growth factor receptor 1 and Nurr1 offers new interactive mechanism in postmitotic development of mesencephalic dopaminergic neurons.
Baron O, Förthmann B, Lee YW, Terranova C, Ratzka A, Stachowiak EK, Grothe C, Claus P, Stachowiak MK
Nurr1 and nuclear FGFR1 physically interact to activate the tyrosine hydroxylase gene, which is essential for dopamine production in developing brain neurons. This molecular partnership suggests a specific mechanism that could potentially be targeted to support dopaminergic neuron development or function.
- Nurr1 and nuclear FGFR1 bind together to regulate the tyrosine hydroxylase gene.
- This interaction promotes dopamine synthesis in developing midbrain neurons.
- The study identifies a potential therapeutic target for neurodevelopmental disorders.
- Research relies on mouse embryonic tissue and cell culture models.
Differentiation of chromaffin progenitor cells to dopaminergic neurons.
Vukicevic V, Schmid J, Hermann A, Lange S, Qin N, Gebauer L, Chunk KF, Ravens U, Eisenhofer G, Storch A, Ader M, Bornstein SR, Ehrhart-Bornstein M
Chromaffin progenitor cells differentiate into functional dopamine-producing neurons that secrete dopamine and fire action potentials. Treatment with retinoic and ascorbic acid doubles dopamine secretion while reducing other catecholamines, suggesting a viable pathway for cell replacement therapies in Parkinson's disease.
- Chromaffin progenitors become mature, firing dopaminergic neurons expressing Nurr1 and Pitx3.
- Retinoic and ascorbic acid double dopamine secretion from these differentiated cells.
- This approach offers a potential source for cell replacement therapies in Parkinson's disease.
Decreased NURR1 and PITX3 gene expression in Chinese patients with Parkinson's disease.
Liu H, Wei L, Tao Q, Deng H, Ming M, Xu P, Le W
This study finds that NURR1 gene expression is significantly lower in the blood of Chinese adults with Parkinson's disease compared to healthy controls. This suggests that reduced NURR1 levels may be a systemic marker associated with the development of Parkinson's disease.
- NURR1 and PITX3 gene expression are significantly decreased in Parkinson's patients' blood cells.
- Lower NURR1 levels correlate with increased Parkinson's risk in male subjects.
- Lower PITX3 levels correlate with increased Parkinson's risk in older subjects.
- The study analyzes human peripheral blood lymphocytes from 255 patients and 211 controls.
NR4A2: effects of an "orphan" receptor on sustained attention in a schizophrenic population.
Ancín I, Cabranes JA, Vázquez-Álvarez B, Santos JL, Sánchez-Morla E, Alaerts M, Del-Favero J, Barabash A
Specific genetic variations in the NR4A2 gene correlate with poorer sustained attention performance, including slower reaction times and reduced accuracy, in patients with schizophrenia. These associations are observed primarily in male subjects and suggest that NR4A2 influences cognitive pathways related to attention.
- NR4A2 variants link to worse sustained attention metrics like reaction time and accuracy.
- Associations appear specific to male subjects within the studied population.
- Study uses human genetic data, providing direct evidence of NR4A2 function in cognition.
- Findings relate to schizophrenia, a different condition than NR4A2 developmental syndromes.
Efficient conversion of astrocytes to functional midbrain dopaminergic neurons using a single polycistronic vector.
Addis RC, Hsu FC, Wright RL, Dichter MA, Coulter DA, Gearhart JD
Researchers successfully convert brain support cells into functional dopamine-producing neurons using a single viral vector carrying three specific genes, including NR4A2. This method demonstrates that astrocytes can be directly reprogrammed into midbrain dopaminergic neurons with high efficiency and correct electrical activity. The study establishes a proof-of-concept for direct in vivo reprogramming as a potential future therapy for neurodegenerative conditions.
- Astrocytes convert to functional dopamine neurons using ASCL1, LMX1B, and NURR1 genes.
- A single viral vector delivers all three transcription factors efficiently.
- Reprogrammed neurons show spontaneous pacemaking and dopamine release.
- This is the first demonstration of single-vector reprogramming to dopaminergic neurons.
The co-transduction of Nurr1 and Brn4 genes induces the differentiation of neural stem cells into dopaminergic neurons.
Tan XF, Jin GH, Tian ML, Qin JB, Zhang L, Zhu HX, Li HM
Forcing neural stem cells to express both Nurr1 and Brn4 genes produces more mature, functional dopaminergic neurons than using Nurr1 alone. This combination improves the cellular quality for potential future cell replacement therapies in Parkinson's disease.
- Nurr1 alone creates immature dopaminergic neurons with limited maturity markers.
- Adding Brn4 co-expression drives these cells toward a mature, functional state.
- The study uses neural stem cells, not human patients or clinical data.
- This is preclinical research focused on optimizing cell therapy techniques.
Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells.
Liu X, Li F, Stubblefield EA, Blanchard B, Richards TL, Larson GA, He Y, Huang Q, Tan AC, Zhang D, Benke TA, Sladek JR, Zahniser NR, Li CY
Researchers successfully converted human skin cells into dopamine-producing neuron-like cells using five specific transcription factors, including Nurr1 (NR4A2). These reprogrammed cells displayed key functional characteristics of dopaminergic neurons and provided symptomatic relief in a rat model of Parkinson's disease. This approach offers a potential future source of cells for transplantation therapies.
- Human fibroblasts convert into dopamine neuron-like cells using five transcription factors.
- Nurr1 (NR4A2) is one of the key factors used in this reprogramming process.
- Reprogrammed cells exhibit correct markers, electrical activity, and dopamine production.
- Treatment improves symptoms in a rat model of Parkinson's disease.
- This method provides a potential source for cell-replacement therapy.
DJ-1 upregulates tyrosine hydroxylase gene expression by activating its transcriptional factor Nurr1 via the ERK1/2 pathway.
Lu L, Sun X, Liu Y, Zhao H, Zhao S, Yang H
This study shows that a specific Parkinson's-related protein (DJ-1) helps produce dopamine by activating the NR4A2/Nurr1 pathway in cells. A common disease-causing mutation in DJ-1 fails to perform this activation, suggesting a broken link in dopamine production. This provides mechanistic insight into how genetic defects might reduce dopamine levels.
- DJ-1 activates Nurr1 (NR4A2) to increase tyrosine hydroxylase, the enzyme that makes dopamine.
- The L166P DJ-1 mutation, linked to Parkinson's, fails to activate this pathway.
- Blocking the ERK1/2 signaling pathway stops DJ-1 from boosting dopamine production.
- Nurr1 is required for DJ-1 to upregulate tyrosine hydroxylase expression.
Signaling of glial cell line-derived neurotrophic factor and its receptor GFRα1 induce Nurr1 and Pitx3 to promote survival of grafted midbrain-derived neural stem cells in a rat model of Parkinson disease.
Lei Z, Jiang Y, Li T, Zhu J, Zeng S
Treating neural stem cells with GDNF boosts the expression of Nurr1 and Pitx3, which promotes the survival and development of dopamine-producing neurons. In a rat model of Parkinson disease, these treated cells successfully integrated and improved motor symptoms.
- GDNF signaling increases Nurr1 and Pitx3 levels in neural stem cells.
- This process enhances the survival and differentiation of dopamine neurons.
- Treated cells reduced motor deficits in a rat Parkinson disease model.
Relationship between sensorimotor gating deficits and dopaminergic neuroanatomy in Nurr1-deficient mice.
Vuillermot S, Feldon J, Meyer U
Mice with reduced Nurr1 levels show sensorimotor gating deficits that correlate with decreased dopamine cell numbers and signaling in the striatum. This confirms that partial loss of NR4A2 disrupts dopaminergic pathways, linking genetic dosage to specific neural circuitry changes.
- Nurr1-deficient mice exhibit reduced prepulse inhibition, a measure of sensorimotor gating.
- Deficits correlate with fewer dopamine cells in the substantia nigra.
- Striatal dopamine transporter and enzyme levels are decreased.
- Findings link NR4A2 dosage directly to dopaminergic neuroanatomy.
- Results model aspects of Parkinson's disease relevant to dopamine loss.
Direct generation of functional dopaminergic neurons from mouse and human fibroblasts.
Caiazzo M, Dell'Anno MT, Dvoretskova E, Lazarevic D, Taverna S, Leo D, Sotnikova TD, Menegon A, Roncaglia P, Colciago G, Russo G, Carninci P, Pezzoli G, Gainetdinov RR, Gustincich S, Dityatev A, Broccoli V
Researchers demonstrate that three specific transcription factors, including Nurr1 (NR4A2), can directly convert skin cells into functional dopaminergic neurons in both mice and humans. This technique bypasses the tumor risks associated with stem cell therapies and produces neurons that release dopamine and exhibit normal electrical activity. The method works on cells from healthy donors as well as Parkinson's disease patients, offering a potential avenue for future cell replacement treatments.
- Three factors including Nurr1 convert skin cells directly into functional dopaminergic neurons.
- The process avoids the tumor risks linked to pluripotent stem cell therapies.
- Generated neurons release dopamine and show normal pacemaker electrical activity.
- The method works on fibroblasts from both healthy donors and Parkinson's patients.
ES cell-derived renewable and functional midbrain dopaminergic progenitors.
Chung S, Moon JI, Leung A, Aldrich D, Lukianov S, Kitayama Y, Park S, Li Y, Bolshakov VY, Lamonerie T, Kim KS
Researchers successfully isolate and expand midbrain dopaminergic progenitor cells from embryonic stem cells that mature into functional dopamine neurons. These transplanted cells integrate into the brain of Parkinson's disease animal models, restore motor function, and do not form tumors.
- Otx2(+)Corin(+) cells expand 1,000-fold while maintaining dopaminergic progenitor identity.
- Transplanted cells differentiate into mature dopamine neurons in living animals.
- Grafted cells improve motor dysfunction in Parkinson's disease mouse and rat models.
- No tumor formation occurs after transplantation of these expanded progenitor cells.
Pten ablation in adult dopaminergic neurons is neuroprotective in Parkinson's disease models.
Domanskyi A, Geissler C, Vinnikov IA, Alter H, Schober A, Vogt MA, Gass P, Parlato R, Schütz G
Deleting the Pten gene in adult mouse dopamine neurons activates mTOR signaling, which protects these cells from damage and restores movement in Parkinson's disease models. This intervention increases dopamine production and maintains the expression of key genes like Nurr1 (NR4A2) that are essential for neuron survival. The study suggests that inhibiting Pten-dependent functions could be a potential therapeutic strategy for neurodegenerative conditions.
- Pten deletion in mouse dopamine neurons activates mTOR signaling and protects against cell death.
- The treatment restores dopamine levels and improves locomotor deficits in Parkinson's disease models.
- Pten ablation increases expression of Nurr1 (NR4A2) and other critical dopamine neuron maintenance genes.
- This is preclinical research conducted exclusively in mice, not humans.
Decreased level of Nurr1 in heterozygous young adult mice leads to exacerbated acute and long-term toxicity after repeated methamphetamine exposure.
Luo Y, Wang Y, Kuang SY, Chiang YH, Hoffer B
Reduced Nurr1 levels in mice make the brain more vulnerable to damage from repeated methamphetamine exposure, particularly when that exposure starts in adolescence. This suggests that having only one working copy of the NR4A2 gene may increase sensitivity to neurotoxic stressors later in life.
- Adolescent drug exposure causes lasting damage to dopamine systems in mice.
- Mice with reduced Nurr1 suffer greater neuronal loss from repeated drug exposure.
- Nurr1 deficiency appears to increase vulnerability to dopaminergic toxicity.
- This is a mouse model study, not human clinical evidence.
Foxa2 and Nurr1 synergistically yield A9 nigral dopamine neurons exhibiting improved differentiation, function, and cell survival.
Lee HS, Bae EJ, Yi SH, Shim JW, Jo AY, Kang JS, Yoon EH, Rhee YH, Park CH, Koh HC, Kim HJ, Choi HS, Han JW, Lee YS, Kim J, Li JY, Brundin P, Lee SH
Combining Nurr1 and Foxa2 genes efficiently produces mature, functional dopamine neurons that survive better and improve movement in rats with Parkinson's disease. This approach creates safer stem cell therapies by reducing the risk of tumor formation from uncontrolled cell division.
- Nurr1 alone fails to fully mature dopamine neurons in human or mouse cells.
- Adding Foxa2 significantly boosts neuron maturity, function, and survival rates.
- Foxa2 forces cells to stop dividing, reducing tumor risks in transplants.
- Transplanted cells reversed motor deficits in a rat Parkinson's model.
Long-term culture and differentiation of CNS precursors derived from anterior human neural rosettes following exposure to ventralizing factors.
Colleoni S, Galli C, Giannelli SG, Armentero MT, Blandini F, Broccoli V, Lazzari G
This study shows that human stem cells can be directed to become dopaminergic neurons in the lab and successfully engraft in Parkinson's disease rat models. It establishes a protocol for generating these specific nerve cells but does not test any treatments or outcomes in humans with NR4A2-related syndromes.
- Human stem cells differentiate into dopaminergic neurons using Shh and FGF8 factors.
- Transplanted precursors engraft and mature in the brains of Parkinsonian rats.
- The research focuses on cell therapy potential for CNS degenerative diseases.
- No human clinical data or NR4A2 patient outcomes are reported.
In vitro and in vivo enhanced generation of human A9 dopamine neurons from neural stem cells by Bcl-XL.
Courtois ET, Castillo CG, Seiz EG, Ramos M, Bueno C, Liste I, Martínez-Serrano A
Adding Bcl-XL to human neural stem cells significantly increases the production of dopamine neurons that resemble those lost in Parkinson's disease. In rat models, these enhanced cells survive transplantation and improve motor symptoms, suggesting a potential pathway for future cell therapies.
- Bcl-XL boosts the yield of mature dopamine neurons from human stem cells.
- Enhanced cells express key genes like NURR1 and PITX3 involved in dopaminergic function.
- Transplanted cells survive and reduce motor asymmetry in Parkinsonian rat models.
- This approach aims to improve cell therapy viability for neurodegenerative conditions.
Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons.
Kadkhodaei B, Ito T, Joodmardi E, Mattsson B, Rouillard C, Carta M, Muramatsu S, Sumi-Ichinose C, Nomura T, Metzger D, Chambon P, Lindqvist E, Larsson NG, Olson L, Björklund A, Ichinose H, Perlmann T
Removing the Nurr1 gene in adult mice causes a slow, progressive loss of dopamine neurons and neurotransmitters. This confirms that Nurr1 is essential for keeping these specific brain cells alive long after they have developed.
- Nurr1 is required to maintain mature dopamine neurons in the adult brain.
- Loss of Nurr1 leads to gradual degeneration of substantia nigra neurons.
- The study uses mouse models, not human clinical data.
- Findings support a biological role for Nurr1 in neuron survival.
Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease.
Friling S, Bergsland M, Kjellander S
Activating the Retinoid X Receptor (RXR) protects dopamine neurons from degeneration in laboratory models of Parkinson's disease. This suggests RXR is a promising target for therapies that could preserve these brain cells.
- RXR ligands protect dopamine neurons from toxin-induced damage in rat and stem cell cultures.
- The protective effect is selective for dopamine neurons and does not work against all stress types.
- Stem cell-derived dopamine cultures provide a reliable platform for testing potential treatments.
- This study uses animal and cell models, not human patients.
Wnt1-lmx1a forms a novel autoregulatory loop and controls midbrain dopaminergic differentiation synergistically with the SHH-FoxA2 pathway.
Chung S, Leung A, Han BS, Chang MY, Moon JI, Kim CH, Hong S, Pruszak J, Isacson O, Kim KS
Researchers identify a specific genetic loop involving Wnt1 and Lmx1a that works with other signals to guide stem cells into becoming midbrain dopamine neurons. This process directly regulates Nurr1 (NR4A2) and Pitx3, which are critical for the development of these specific brain cells. The study demonstrates that activating multiple pathways together significantly improves the production of these neurons in laboratory settings.
- Wnt1 and Lmx1a form a loop that regulates Nurr1 (NR4A2) during neuron development.
- This loop works synergistically with the SHH-FoxA2 pathway to boost dopamine neuron creation.
- The findings come from stem cell models and embryonic mice, not human patients.
- Nurr1 and Pitx3 are direct targets of this regulatory mechanism in midbrain development.
Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor.
Gibrat C, Bousquet M, Saint-Pierre M, Lévesque D, Calon F, Rouillard C, Cicchetti F
Cystamine protects dopamine-producing neurons in mice by increasing brain-derived neurotrophic factor (BDNF) levels. This study provides preclinical evidence that cystamine may preserve Nurr1 expression and prevent neuronal loss in a Parkinson's disease model.
- Cystamine increases BDNF mRNA in the substantia nigra of mice.
- Low-dose cystamine protects against MPTP-induced dopamine neuron loss.
- Higher doses show no benefit or cause non-specific effects.
- Protection correlates with preserved Nurr1 mRNA expression.
- Results suggest BDNF up-regulation as the key mechanism.
Vesicular monoamine transporter 2 and dopamine transporter are molecular targets of Pitx3 in the ventral midbrain dopamine neurons.
Hwang DY, Hong S, Jeong JW, Choi S, Kim H, Kim J, Kim KS
The transcription factor Pitx3 directly activates the genes for dopamine transporters in midbrain neurons, working alongside Nurr1 to regulate dopamine function. This study identifies a specific molecular mechanism by which these two proteins coordinate to maintain healthy dopamine signaling pathways.
- Pitx3 directly activates vesicular monoamine transporter 2 and dopamine transporter genes.
- Loss of Pitx3 significantly reduces the expression of key dopamine transporters.
- Pitx3 and Nurr1 likely coordinate to regulate dopamine neuron survival and function.
- This mechanism is observed in mouse models of midbrain dopamine neurons.
Generation of dopamine neurons with improved cell survival and phenotype maintenance using a degradation-resistant nurr1 mutant.
Jo AY, Kim MY, Lee HS, Rhee YH, Lee JE, Baek KH, Park CH, Koh HC, Shin I, Lee YS, Lee SH
Engineered Nurr1 proteins that resist cellular degradation significantly improve the survival and stability of dopamine neurons in laboratory settings. This modification prevents the loss of therapeutic potential often seen when these cells are transplanted, suggesting a viable strategy for future cell-based treatments.
- Nurr1 protein naturally degrades via Akt-mediated phosphorylation during neuron development.
- A mutant Nurr1 resists this degradation and maintains high protein levels longer.
- Neurons with stable Nurr1 show enhanced survival and sustained dopamine phenotypes.
- The approach improves cell viability in both lab cultures and animal models.
Dopamine genes and nicotine dependence in treatment-seeking and community smokers.
Bergen AW, Conti DV, Van Den Berg D, Lee W, Liu J, Li D, Guo N, Mi H, Thomas PD, Lessov-Schlaggar CN, Krasnow R, He Y, Nishita D, Jiang R, McClure JB, Tildesley E, Hops H, Tyndale RF, Benowitz NL, Lerman C, Swan GE
This study identifies a genetic interaction between NR4A2 and SLC6A3 that influences nicotine dependence severity in smokers. The findings confirm that the NR4A2 protein regulates the transcription of the dopamine transporter gene, providing mechanistic insight into dopaminergic pathways.
- NR4A2 variants interact with SLC6A3 to affect nicotine dependence levels.
- The study confirms NURR1 regulates dopamine transporter gene transcription.
- Each significant SNP accounts for approximately 1% of variance in dependence scores.
- Results are based on human genetic data from smokers, not clinical trials.
A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death.
Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG, Gage FH, Glass CK
Nurr1 protects dopaminergic neurons from inflammation-induced death by suppressing pro-inflammatory mediators in microglia and astrocytes. Reduced Nurr1 levels lead to exaggerated inflammatory responses that cause neuronal loss, providing a mechanistic link between Nurr1 mutations and neurodegeneration.
- Nurr1 inhibits pro-inflammatory mediators in microglia and astrocytes.
- Reduced Nurr1 causes exaggerated inflammation leading to dopaminergic neuron death.
- Nurr1 recruits CoREST to repress inflammatory gene transcription via NF-kappaB-p65.
- This mechanism explains how Nurr1 mutations contribute to Parkinson's disease pathology.
A Nurr1 pathway for neuroprotection.
Bensinger SJ, Tontonoz P
Nurr1 protects dopaminergic neurons by suppressing inflammatory gene expression in astrocytes and microglia. This mechanism suggests that reducing neuroinflammation could be a therapeutic strategy for conditions involving Nurr1 dysfunction.
- Nurr1 suppresses inflammation in brain support cells to protect dopamine neurons.
- This pathway offers a potential target for treating neurodegenerative symptoms.
- The study uses mouse models to demonstrate this protective mechanism.
Differentiation of dopaminergic neurons from human embryonic stem cells: modulation of differentiation by FGF-20.
Shimada H, Yoshimura N, Tsuji A, Kunisada T
This study demonstrates that adding FGF-20 and FGF-2 to human embryonic stem cell cultures improves the generation of midbrain dopaminergic neurons. The treatment increases key transcription factors like NURR1, which is the protein affected by NR4A2 mutations, suggesting a potential pathway for future cell-based therapies.
- FGF-20 and FGF-2 enhance differentiation of human stem cells into dopaminergic neurons.
- Treatment boosts expression of NURR1, PITX3, LMX1B, and EN1 transcription factors.
- The method works without support cells, offering a cleaner protocol for neuron production.
- Results aim to improve cell transplantation strategies for Parkinson's disease.
Characterisation of a novel NR4A2 mutation in Parkinson's disease brain.
Sleiman PM, Healy DG, Muqit MM, Yang YX, Van Der Brug M, Holton JL, Revesz T, Quinn NP, Bhatia K, Diss JK, Lees AJ, Cookson MR, Latchman DS, Wood NW
This study identifies a specific NR4A2 mutation found in Parkinson's disease patients that reduces gene expression and disrupts nervous system development pathways. The findings confirm that this genetic variant impairs the protein's ability to protect neurons from stress, linking reduced NR4A2 levels directly to cellular dysfunction.
- Researchers screened 409 Parkinson's patients and found a novel NR4A2 mutation in the gene's regulatory region.
- The mutation significantly reduces NR4A2 mRNA expression in both cell cultures and human brain tissue.
- Reduced NR4A2 levels downregulate genes critical for nervous system development and synaptic transmission.
- The mutant protein loses its ability to protect neurons against apoptotic stress compared to the normal version.
Pitx3 potentiates Nurr1 in dopamine neuron terminal differentiation through release of SMRT-mediated repression.
Jacobs FM, van Erp S, van der Linden AJ, von Oerthel L, Burbach JP, Smidt MP
This study identifies Pitx3 as a critical partner that activates Nurr1 (NR4A2) to drive the development of dopamine-producing neurons. It shows that without Pitx3, Nurr1 remains inactive, but blocking specific repressive mechanisms can restore its function.
- Pitx3 and Nurr1 work together to activate genes necessary for dopamine neuron development.
- Nurr1 alone cannot fully activate these genes; it requires Pitx3 for complete function.
- Pitx3 removes a repressor complex that normally keeps Nurr1 inactive.
- Blocking this repression restores gene activity even without Pitx3 present.
Role of Nurr1 and Ret in inducing rat embryonic neural precursors to dopaminergic neurons.
Li L, Su Y, Zhao C, Xu Q
This study shows that Nurr1 and Ret work together in rat brain cells to help develop dopamine-producing neurons. Nurr1 drives the production of these specific nerve cells, while Ret helps them mature by increasing markers associated with dopamine function.
- Nurr1 increases the number of developing dopamine neurons in rat embryonic cells.
- Ret expression depends on Nurr1 but does not further increase neuron numbers.
- Ret promotes neuronal maturation by upregulating the dopamine transporter gene.
- The findings rely entirely on rat cell cultures, not human patients.